Hot Investor Mandate: Cross-Border VC Invests Up to $10M, With Strong Interest in Chronic Disease Management, Digital Health, AI, and More

13 Jul

A venture capital firm headquartered in Taiwan is focused on investing in tech-related companies such as AI, biotechnology, fintech, semiconductors, smart manufacturing, etc. The firm is stage agnostic, however, within life science and healthcare, the firm is also focusing on early-stage companies from Pre-Series A to Series B. Typical check sizes range from $1M-10M, although usually it will be $3M-5M to start. The firm participates in co-investing, but 60-70% of the time, the firm will lead. The firm is looking at companies in the U.S., Japan, Taiwan, and Europe, with the goal of creating a cross-border ecosystem that helps healthcare and biotech companies thrive. The firm is also willing to help later-stage companies with commercialization and connect with Taiwanese partners and key players in the U.S.

The firm invests in fundamental science driven companies with a technology focus. The main sectors the company focuses on are chronic disease management/treatment, AI and/or digital health, and service-based companies. Main indication areas include oncology, metabolic diseases, and autoimmune diseases, however indication areas are not limited to those listed. The firm is also open to orphan diseases, however, it has to be a platform that addresses orphan diseases to validate the technology. The firm looks at in-development and clinical stages as well as pre-approval, but they may not be interested in very early stages. For drugs, the firm requires proof of biology with an established animal model data.

The firm may invest in young teams to grow with them, however most of the time, the firm prefers companies to have an experienced team in place. The firm also requires taking a board seat, if not, at least an observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a comment